Similar articles

• Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute.

  Goldin A, Venditti JM, Macdonald JS, Muggia FM, Henney JE, Devita VT Jr. Goldin A, et al. Eur J Cancer (1965). 1981 Feb;17(2):129-42. doi: 10.1016/0014-2964(81)90027-x. Eur J Cancer (1965). 1981. PMID: 6894902 No abstract available.
• A prospective screening program: current screening and its status.

  Goldin A, Venditti JM. Goldin A, et al. Recent Results Cancer Res. 1981;76:176-91. doi: 10.1007/978-3-642-81565-2_15. Recent Results Cancer Res. 1981. PMID: 7232850 No abstract available.
• Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions.

  Venditti JM, Wesley RA, Plowman J. Venditti JM, et al. Adv Pharmacol Chemother. 1984;20:1-20. doi: 10.1016/s1054-3589(08)60263-x. Adv Pharmacol Chemother. 1984. PMID: 6398966 Review. No abstract available.
• [Introduction of new screening system in National Cancer Institute].

  Tsukagoshi S. Tsukagoshi S. Gan To Kagaku Ryoho. 1984 May;11(5):1134-9. Gan To Kagaku Ryoho. 1984. PMID: 6539100 Japanese. No abstract available.
• Investigational drugs under study by the United States National Cancer Institute.

  Carter SK, Slavik M. Carter SK, et al. Cancer Treat Rev. 1976 Mar;3(1):43-60. doi: 10.1016/s0305-7372(76)80016-3. Cancer Treat Rev. 1976. PMID: 62615 Review. No abstract available.